Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWJ0IH)

• Drug Name: REGN-421 Drug Info
• Synonyms: Dll4 antibody; Dll4-Fc; Delta-like ligand 4 antibody (VelociSuite), Regeneron, sanofi-aventis

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMWJ0IH

Molecule-Related Drug Atlas

Drug(s) Targeting Delta-like protein 4 (DLL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dilpacimab	DMCATH2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
Navicixizumab	DMZ2G69	Colorectal cancer	2B91.Z	Phase 1	[4]
ABT-165	DMQ3O1U	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
NOV1501	DME2QUZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
OMP-21M18	DMX1D0S	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Delta-like protein 4 (DLL4)	TTV23LH	DLL4_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT00871559) A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies. U.S. National Institutes of Health.
• [2] J Clin Oncol 31, 2013 (suppl; abstr 2502).
• [3] Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538.
• [7] National Cancer Institute Drug Dictionary (drug id 614677).